

RESEARCH ARTICLE | *Translational Physiology*

Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation

Naohiro Oda,¹  Nobuaki Miyahara,^{2,3} Akihiko Taniguchi,¹ Daisuke Morichika,¹ Satoru Senoo,¹ Utako Fujii,¹ Junko Itano,¹ Yuka Gion,^{2,4} Katsuyuki Kiura,³ Arikiko Kanehiro,^{1,5} and Yoshinobu Maeda¹

¹Department of Hematology, Oncology, Allergy, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; ²Department of Medical Technology, Okayama University Graduate School of Health Sciences, Okayama, Japan; ³Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan; ⁴Division of Pathophysiology, Okayama University Graduate School of Health Sciences, Okayama, Japan; and ⁵Department of Allergy and Respiratory Medicine, Okayama Rosai Hospital, Okayama, Japan

Submitted 24 August 2018; accepted in final form 19 December 2018

Oda N, Miyahara N, Taniguchi A, Morichika D, Senoo S, Fujii U, Itano J, Gion Y, Kiura K, Kanehiro A, Maeda Y. Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation. *Am J Physiol Lung Cell Mol Physiol* 316: L407–L417, 2019. First published January 3, 2019; doi:10.1152/ajplung.00386.2018.—Neuropeptide Y (NPY) is a neurotransmitter that is widely expressed in the brain and peripheral nervous system. Various immune cells express the NPY Y₁ receptor. NPY modulates these cells via its Y₁ receptor; however, involvement of NPY in the pathophysiology of bronchial asthma, particularly airway hyperresponsiveness (AHR), has not been defined. NPY-deficient and wild-type mice were intranasally sensitized and challenged to house dust mite (HDM) extract, and airway responses were monitored. After sensitization and challenge, NPY-deficient mice showed significantly lower AHR than wild-type mice, and numbers of eosinophils and levels of type 2 cytokines [interleukin (IL)-4, IL-5, and IL-13] in bronchoalveolar lavage fluid were significantly lower. Type 2 cytokine production from splenic mononuclear cells of HDM-sensitized mice was also significantly lower in NPY-deficient mice. Flow cytometry analysis showed that the number of CD4 T cells and CD11c⁺ antigen-presenting cells (APCs) was significantly lower in the lungs of NPY-deficient mice than in wild-type mice following sensitization and challenge. Significantly fewer CD11c⁺ APCs phagocytosed HDM in the mediastinal lymph nodes of NPY-deficient mice than in those of wild-type mice. Treatment with BIBO-3304, a NPY receptor antagonist, significantly suppressed development of HDM-induced AHR and inflammation in wild-type mice. These data identify an important contribution of NPY to allergen-induced AHR and inflammation through accumulation of dendritic cells in the airway and promotion of the type 2 immune response. Thus, manipulating NPY represents a novel therapeutic target to control allergic airway responses.

airway hyperresponsiveness; allergic airway inflammation; asthma; NPY; Y₁ receptor antagonist

INTRODUCTION

Bronchial asthma is characterized by airway inflammation and airway hyperresponsiveness (AHR). Airway inflammation results from the accumulation of activated eosinophils and T cells at the site of inflammation. T cells, particularly T-helper (Th) type 2 cells, which release interleukin (IL)-4, IL-5, and IL-13, play pivotal roles in the development of allergic airway inflammation and AHR (1, 2, 21). Current management based on inhaled corticosteroids and long-acting β_2 -adrenergic agonists is effective in controlling bronchial asthma in most patients. However, 5–10% of patients with asthma respond poorly to high doses of inhaled corticosteroid and/or systemic corticosteroid and develop prolonged inflammatory cell infiltration in the airways (15). In such patients with so-called “severe asthma” or “refractory asthma,” uncontrolled and frequently exacerbated asthmatic symptoms greatly impair quality of life and have a considerable impact on health care costs (17). Therefore, development of an effective and novel pharmacotherapy is warranted.

Neuropeptide Y (NPY) is a 36-amino-acid peptide neurotransmitter that is widely expressed in the brain. NPY regulates a broad range of functions, such as feeding, anxiety, memory, and circadian rhythms. NPY is released from peripheral sympathetic nerves and is important in the regulation of blood pressure and energy homeostasis (23). Immunohistochemistry of lung biopsies has shown that lung tissue is highly innervated with NPY-positive nerve fibers entering the bronchus-associated lymphoid tissue, the branches of the pulmonary artery (13), and the respiratory tract (29). During sympathetic stimulation, NPY is coreleased with norepinephrine in the lymph nodes close to immune cells (9, 38). The Y₁ receptor, an NPY receptor, is expressed on various immune cells, such as B cells, CD4 and CD8 T cells, macrophages, dendritic cells (DCs), natural killer cells, and mast cells (36), and NPY acts on these cells via its Y₁ receptor (36). NPY enhances IL-4 production, inhibits interferon (IFN)- γ production by Th cells (18), and increases migration of immature DCs derived from human peripheral blood, which promotes Th2 differentiation (3). Thus, NPY is a potent immunomodulator that skews the immune profile toward type 2 immunity.

Address for reprint requests and other correspondence: N. Miyahara, Dept. of Medical Technology, Okayama Univ. Graduate School of Health Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan (e-mail: miyahara@md.okayama-u.ac.jp).

Serum NPY levels increase in asthmatic patients (6, 7), and NPY polymorphisms are associated with an increased risk for asthma in overweight subjects (16) and young adults (25). Ovalbumin (OVA)-induced eosinophilic airway inflammation was reported to be lower in NPY- or Y₁-deficient mice compared with wild-type mice (26). Thus, NPY might be involved in eosinophilic airway inflammation. However, the role of NPY in the pathophysiology of bronchial asthma has not been well defined. In particular, the AHR, the most important phenotype of asthma, airway responses induced by a protease allergen such as house dust mite (HDM) extract, and the mechanisms of how NPY contributes to allergic airway responses have not been elucidated.

In this study, we investigated the role of NPY in allergen-induced AHR and inflammation in HDM-sensitized and -challenged mice. We assessed NPY-deficient (NPY^{-/-}) mice and the effects of treatment with an NPY receptor antagonist and showed that both approaches attenuated development of AHR, airway inflammation, and the accumulation of CD11c⁺ antigen-presenting cells (APCs) in the airway. Thus, manipulating NPY may be beneficial for controlling asthmatic responses.

MATERIALS AND METHODS

Animals. NPY^{-/-} mice (129 background) were purchased from Charles River Laboratories (Yokohama, Japan). The NPY^{-/-} mice were then backcrossed to C57BL/6J mice (Charles River) for nine generations. Eight- to 10-wk-old female NPY^{-/-} mice and C57BL/6J (NPY^{+/+} mice) were used in all experiments. NPY^{-/-} mice were viable and displayed normal reproductive fitness without a striking phenotype. No spontaneous disease was observed in the NPY^{-/-} mice up to 6 mo of age, when they were housed under specific pathogen-free conditions. All experiments were performed in accordance with the National Institutes of Health (NIH) guidelines. All procedures were conducted under a protocol approved by the institutional animal care and use committee of Okayama University (Okayama, Japan).

Experimental protocol (sensitization and airway challenge). The HDM-induced airway-inflammation mouse model was prepared with reference to a previous report (12). NPY^{-/-} and NPY^{+/+} mice were sensitized with 15 µg of HDM extract (Greer Laboratories, Lenoir, NC) in 30 µl of PBS by intranasal instillation on days 0–2. The mice were subsequently challenged with 5 µg of HDM extract in 30 µl of PBS by intranasal instillation on days 14–17. AHR was measured as described below at 24 h after the last challenge, and samples were collected for further analyses.

Administration of the Y₁ receptor antagonist. The Y₁ receptor antagonist BIBO-3304 [(R)-N-[[4-(aminocarbonylaminoethyl)-phenyl] methyl]-N₂-(diphenylacetyl)-argininamide trifluoroacetate; (Santa Cruz Biotechnology, Dallas, TX) or vehicle was administered by intraperitoneal injection at a rate of 0.1 or 1 mg/kg in 200 µl of PBS one time per day from day 13 to 17.

Determination of airway responsiveness. Airway responsiveness was assessed by measuring changes in lung resistance in response to increasing doses of inhaled methacholine (10) using a FlexiVent small-animal ventilator (SCIREQ, Montreal, PQ, Canada). Before testing, the mice were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and xylazine (10 mg/kg), tracheostomized, and mechanically ventilated. No significant differences in baseline values were observed among the different groups.

Bronchoalveolar lavage. Immediately after assessing airway function, the lungs were lavaged with Hanks' balanced salt solution (2 × 1 ml, 37°C) via a tracheal tube. The volume of bronchoalveolar lavage (BAL) fluid collected was measured in each sample, and the number of cells in the BAL fluid were counted. Cytospin slides were stained

with May-Giemsa stain and differentiated in a blinded fashion by counting at least 200 cells under a light microscope (34).

Lung histology. The lungs were fixed in 10% formalin, cut around the main bronchus, and embedded in paraffin blocks. The slides were stained with hematoxylin-eosin and periodic acid-Schiff (PAS) to identify mucus-containing cells under a light microscope. The number of mucus-containing cells (goblet cells) was counted in >10 bronchioles in 10 high-power fields/animal by measuring the length of the epithelium defined along the basement membrane and luminal area using the NIH Image Analysis system (14).

Lung homogenates. Lung tissues were frozen at -80°C immediately after euthanasia. The lung tissues were mixed with a PBS-0.1% Triton X-100 solution containing proteinase inhibitors at a 1:2.5 ratio (wt/vol) (Sigma-Aldrich, St. Louis, MO). The specimens were homogenized and then centrifuged at 14,000 rpm for 30 min. The supernatants were used to analyze cytokine levels by enzyme-linked immunosorbent assay (ELISA), as described below (20).

Culture of splenic mononuclear cells. The spleens of HDM-sensitized mice were removed and placed in PBS. The cells were dispersed, and mononuclear cells (MNCs) were separated by density gradient cell centrifugation using Histopaque (Sigma-Aldrich). The cells were washed, counted, and resuspended to a fixed concentration in RPMI-1640 (Wako Pure Chemical Industries, Osaka, Japan) containing heat-inactivated 10% fetal calf serum (FCS) and penicillin/streptomycin. The cells (4 × 10⁵) were plated in each well of a 96-well round-bottom plate and cultured at 37°C in a 5% CO₂ atmosphere in the presence or absence of 10 mg/ml HDM extract. The supernatants were removed at 48 h after the last challenge, and cytokine levels were analyzed by ELISA as described below (19).

Measurement of cytokines and chemokines. Cytokine levels in the BAL fluid were measured using ELISA. All cytokine and chemokine ELISAs were performed according to the manufacturers' directions. The limits of detection were 2 pg/ml for IL-4, 7 pg/ml for IL-5, 1.5 pg/ml for IL-13, 2 pg/ml for IFN-γ, 5 pg/ml for IL-17A, 2.8 pg/ml for IL-33, 0.71 pg/ml for thymic stromal lymphopoietin (TSLP), and 0.01 ng/ml for NPY. All kits, except that for NPY (EMD Millipore, Billerica, MA), were purchased from R&D Systems (Minneapolis, MN). Lung homogenates were prepared as described previously (20).

Lung cell isolation. Lungs of HDM-sensitized and -challenged mice were separated from the associated lymph nodes, removed, and placed in PBS containing 10% heat-inactivated FCS. The lung tissues were minced and incubated for 1 h at 37°C in 5 ml PBS containing 0.05% collagenase I (Sigma-Aldrich). The lung tissues were dispersed by passing through a 20-gauge needle several times, and the suspensions were strained through a cell strainer. The pulmonary MNCs were isolated by density-gradient cell centrifugation over Histopaque (Sigma-Aldrich) (11).

Flow cytometry. The cells were incubated with APC-conjugated anti-CD3, phycoerythrin (PE)-conjugated anti-CD8, FITC-conjugated anti-CD4, APC-conjugated anti-CD11b, and PE-conjugated anti-CD11c antibodies (BD Biosciences, San Diego, CA) and then analyzed by flow cytometry using a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany).

Analyses of group 2 innate lymphoid cells. The cells isolated from digested lungs were stained with biotin-conjugated antibody mixtures for lineage markers (CD4, CD5, CD8, CD11c, CD11b, CD19, NK1.1, Gr-1, TER119, FcεRI, and B220), Pacific blue-conjugated anti-Sca-1, PECy7-conjugated c-Kit (CD117), APC-conjugated anti-IL-7R (CD127), FITC-conjugated anti-T1/ST2, APC- and Cy7-conjugated anti-CD25, and PE-conjugated anti-streptavidin and analyzed using the MACSQuant Analyzer. Lin⁻Scac-KitIL-7RCD25ST2^{dim} cells were identified as lung innate lymphoid cells (ILC2s) (31). The data were analyzed using FlowJo software (TreeStar, Ashland, OR). APC- and Cy7-conjugated anti-CD25; Pacific blue-conjugated anti-Sca-1; biotin-conjugated anti-CD4, anti-CD5, anti-CD8, anti-CD11b, anti-NK1.1, anti-Gr-1, anti-TER119, and anti-B220; and PE-conjugated anti-streptavidin were obtained from BD Biosciences. FITC-conju-

gated anti-T1/ST2 was obtained from MD Bioscience (St. Paul, MN). APC-conjugated anti-IL-7R and biotin-conjugated anti-FcεRI were obtained from BioLegend (San Diego, CA). PECy7-conjugated c-Kit was purchased from eBioscience (La Jolla, CA). Biotin-conjugated anti-CD11c and anti-CD19 were obtained from TONBO Biosciences (San Diego, CA).

DC migration assay. DC migration from the lungs to the mediastinal lymph nodes (MLNs) was analyzed. The HDM extract was labeled with a DyLight 405 Microscale Protein Labeling kit (Thermo Scientific, Waltham, MA). NPY^{-/-} and NPY^{+/+} mice were sensitized with unlabeled HDM extract on days 0–2 and were challenged with labeled HDM extract on days 14–17. The cells were harvested from the MLNs at 24 h after the challenge and analyzed by flow cytometry.

Immunohistochemistry for NPY. Immunohistochemistry was performed on paraffin sections using an automated Bond Max stainer (Leica Biosystems, Melbourne, Australia) with mouse monoclonal anti-NPY antibody (ab112373, dilution 1:1,000; Abcam, Cambridge, UK) as the primary antibody. NPY-positive cells were examined under light microscopy (final magnification: ×400). Evaluation of immunostaining was performed by an expert pathologist (Gion).

Statistical analysis. All results are expressed as means ± SE. Analysis of variance was used to determine differences between the groups. Pairs of samples distributed parametrically were compared using the unpaired two-tailed Student's *t*-test, and samples distributed nonparametrically were compared using the Mann-Whitney *U*-test. *P* values <0.05 were considered significant.

RESULTS

AHR and allergic airway inflammation decrease in NPY^{-/-} mice. AHR was monitored at 24 h after the last HDM challenge in NPY^{+/+} and NPY^{-/-} mice. Sensitization and challenge by intranasal administration of HDM extract increased AHR in NPY^{+/+} mice, as shown by a significant increase in lung resistance compared with that in nonsensitized and nonchallenged mice (Fig. 1A). By contrast, sensitized and challenged NPY^{-/-} mice developed less of an increase in lung resistance compared with sensitized and challenged NPY^{+/+} mice, but, nonetheless, the changes were significantly greater than in NPY^{-/-} mice that were nonsensitized and nonchallenged.

We assessed BAL fluid following sensitization and HDM challenge. Eosinophils increased significantly in sensitized and challenged mice compared with nonsensitized and nonchallenged mice. However, the number of eosinophils was significantly lower in the BAL fluid of NPY^{-/-} mice than in that of NPY^{+/+} mice (Fig. 1B). The number of PAS-positive goblet cells was also significantly lower in NPY^{-/-} mice compared with numbers in NPY^{+/+} mice following sensitization and HDM challenge (Fig. 1, C and D).

Airway cytokine levels. Sensitization and challenge with HDM extract resulted in significant increases in IL-4, IL-5, and IL-13 levels in NPY^{+/+} mice. By contrast, NPY^{-/-} mice had significantly lower levels of IL-4, IL-5, and IL-13 following sensitization and challenge (Fig. 2, A–C). Levels of IFN-γ and IL-17A did not differ between NPY^{-/-} and NPY^{+/+} mice (Fig. 2, D and E).

Splenic MNCs from NPY^{-/-} mice release lower levels of Th2 cytokines. To determine whether the attenuated Th2 cytokine secretion observed in NPY^{-/-} mice was the result of impaired Th2 cytokine production, we assessed cytokine production in splenic MNCs in vitro. The levels of IL-5, IL-13, and IFN-γ from HDM restimulated splenic MNCs in NPY^{-/-} mice were significantly lower than in those of NPY^{+/+} mice

(Fig. 2, G–I). No significant differences were observed in the IL-4 levels of the two strains of mice, although a lower trend was observed in NPY^{-/-} mice (Fig. 2F). These data imply that NPY contributes to systemic sensitization of Th2 cells.

Number of CD4 T cells and CD11c⁺ APCs in the lungs decreases in NPY^{-/-} mice. To determine whether the accumulation of T cells and CD11c⁺ APCs in the airways of sensitized and challenged mice was affected by NPY expression, we assessed the number of T cells and CD11c⁺ cells in the lungs. Numbers of CD4 T cells and CD11c⁺ APCs were significantly lower in NPY^{-/-} mice than in NPY^{+/+} mice following sensitization and challenge (Fig. 3, A and C); however, numbers of CD8⁺ T cells in the two strains of mice did not differ (Fig. 3B).

Migration of CD11c⁺ APCs from lungs to the MLNs is attenuated in NPY^{-/-} mice. NPY induces migration of human DCs (3); therefore, we investigated migration of DCs in this model. The number of violet⁺ and CD11c⁺ APCs that phagocytosed labeled HDM in the MLNs of NPY^{-/-} mice was significantly lower in sensitized and labeled HDM-challenged mice than in NPY^{+/+} mice (Fig. 4B).

These data indicate that NPY plays a crucial role in the migration of DCs to regional lymph nodes, mediating type 2 immune responses, and eliciting allergic airway responses.

Numbers of ILC2s and IL-33 levels in the lungs. Numbers of ILC2s and IL-33 levels increased significantly in sensitized and challenged mice compared with nonsensitized and nonchallenged mice. However, there were no differences between NPY^{+/+} and NPY^{-/-} mice (Fig. 5, A–C).

NPY expression in lung tissue. NPY expression in NPY^{+/+} mice was evaluated by immunohistochemistry 24 h after the last challenge (Fig. 5D). NPY expression was found mainly in alveolar walls, vascular endothelial cells, and some of the inflammatory cells, including mononuclear cells and granulocytes around the bronchus of HDM-sensitized and -challenged NPY^{+/+} mice (Fig. 5D, c–e), whereas relatively few NPY⁺ cells were detected in nonsensitized and nonchallenged NPY^{+/+} mice (Fig. 5D, a and b).

Y₁ receptor antagonist suppresses AHR, allergic airway inflammation, and cytokine levels in the lungs. We assessed the AHR of HDM-sensitized and -challenged mice treated with vehicle, low-dose Y₁ receptor antagonist (0.1 mg·kg⁻¹·day⁻¹), and high-dose Y₁ receptor antagonist (1 mg·kg⁻¹·day⁻¹) at 24 h after the last HDM challenge. The mice treated with vehicle developed AHR more frequently than did the nonsensitized and nonchallenged mice. Administering the high-dose Y₁ receptor antagonist significantly attenuated the increase in AHR compared with the vehicle-treated mice following sensitization and challenge (Fig. 6A).

The number of inflammatory cells in BAL fluid was assessed in vehicle- and Y₁ receptor-antagonist-treated mice. The number of total cells, lymphocytes, and eosinophils was significantly lower in the BAL fluid of high-dose Y₁ receptor antagonist-treated mice that were sensitized and challenged compared with numbers in vehicle-treated mice (Fig. 6B). The number of PAS-positive goblet cells was significantly lower in high-dose Y₁ receptor antagonist-treated mice than in the vehicle-treated mice following sensitization and challenge with HDM extract (Fig. 6, C and D).

We then measured cytokine levels in BAL fluid using ELISA. Sensitization and challenge with HDM extract resulted in significant increases in IL-5 and IL-13 levels in the




Fig. 1. Neuropeptide Y (NPY)^{-/-} mice develop reduced airway hyperresponsiveness (AHR) and airway inflammation following sensitization and challenge. **A**: AHR in NPY^{+/+} and NPY^{-/-} mice after sensitization and challenge with house dust mite (HDM). After the last challenge (24 h), lung resistance was monitored in response to increasing concentrations of inhaled methacholine, as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 8-12$ in each group). $*P < 0.05$. **B**: cellular composition in bronchoalveolar lavage fluid. Values are means $\pm$ SE ($n = 8-12$ in each group). Significant differences ($P < 0.05$) vs. NPY^{+/+} PBS and NPY^{-/-} PBS mice (*) and vs. NPY^{+/+} HDM mice (#). **C**: development of goblet cell metaplasia in the airways of NPY^{+/+} and NPY^{-/-} mice. **D**: goblet cell metaplasia was quantified in periodic acid-Schiff (PAS)-stained sections, as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 5$ in each group). Significant differences ($P < 0.05$) vs. NPY^{+/+} PBS and NPY^{-/-} PBS mice (*) and vs. NPY^{+/+} HDM mice (#). Mac, macrophage; Lym, lymphocyte; Neu, neutrophil; Eos, eosinophil.

vehicle-treated mice. By contrast, mice treated with the high-dose Y₁ receptor antagonist showed significantly lower levels of IL-5 and IL-13 following sensitization and challenge (Fig. 6, E–G).

Y₁ receptor antagonist suppresses CD11c⁺ APCs in the lungs. To determine whether accumulation of immune cells in the airways of sensitized and challenged mice was affected by the Y₁ receptor antagonist treatment, we assessed the number

of T cells and CD11c⁺ APCs in the lungs. The number of CD11c⁺ APCs was significantly lower in the mice treated with the high-dose Y₁ receptor antagonist than in the mice treated with vehicle following sensitization and challenge, although the number of CD4 T cells and CD8 T cells did not differ among the groups (Fig. 7, A–C). These data imply that the NPY-Y₁ axis contributes to migration of DCs to the airway and induces allergic airway responses.




Fig. 2. Cytokine levels in bronchoalveolar lavage (BAL) fluid and the lung and cytokine production from splenic mononuclear cells. A–E: T-helper type 2 (Th2) cytokine levels [interleukin (IL)-4, IL-5, and IL-13] in bronchoalveolar lavage (BAL) fluid, interferon (IFN)- γ , and IL-17 levels in the lung were measured by ELISA, as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 8$ –12 in each group). Significant differences ($P < 0.05$) vs. neuropeptide Y (NPY)^{+/+} PBS and NPY^{-/-} PBS mice (*) and vs. NPY^{+/+} house dust mite (HDM) mice (#). F–I: Th2 cytokine levels (IL-4, IL-5, and IL-13) and IFN- γ levels in supernatants from spleen cultured in the presence or absence of HDM (10 mg/ml) determined by ELISA. Values are means $\pm$ SE ($n = 3$ –4 in each group). * $P < 0.05$.

DISCUSSION

In this study, we demonstrated that NPY contributes to both systemic sensitization and local activation of Th2 cells, as well as to the accumulation of CD11c⁺ APCs in the airways and migration of CD11c⁺ APCs to MLNs following sensitization

and challenge with HDM extract. These data identify the important contribution of NPY to allergen-induced AHR and airway inflammation through migration of DCs to regional lymph nodes and promotion of the type 2 immune response. We also demonstrated for the first time that a Y₁ receptor




Fig. 3. No. of T cells and CD11c⁺ antigen-presenting cells (APCs) in the lung following sensitization and challenge. *A* and *B*: no. of CD4 and CD8 T cells in the lung of neuropeptide Y (NPY)^{+/+} and NPY^{-/-} mice after sensitization and challenge. No. of cells in the lung were determined as described in MATERIALS AND METHODS. Values are means ± SE (*n* = 6–7 in each group). Significant differences (*P* < 0.05) vs. NPY^{+/+} PBS and NPY^{-/-} PBS mice (*) and vs. NPY^{+/+} house dust mite (HDM) mice (#). *C*: no. of CD11c⁺ cells in the lungs of NPY^{+/+} and NPY^{-/-} mice following sensitization and challenge. Values are means ± SE (*n* = 4–5 in each group). Significant differences (*P* < 0.05) vs. NPY^{+/+} PBS and NPY^{-/-} PBS mice (*) and vs. NPY^{+/+} HDM mice (#).

antagonist suppressed allergen-induced AHR and airway inflammation, which are important bronchial asthma phenotypes. Thus, manipulating NPY represents a novel therapeutic target to control allergic airway responses.

T cells, particularly Th2 cells that release IL-4, IL-5, and IL-13, play pivotal roles in the development of AHR and eosinophilic inflammation (1, 2, 21). Furthermore, DCs, representative of lung APCs, are critical for activating lung immune responses (30). In our study, the number of CD4 T cells in the lungs and the levels of Th2 cytokines in BAL fluid were significantly lower in NPY^{-/-} mice than in NPY^{+/+} mice. The number of CD11c⁺ APCs, which are recognized as DCs in the lung, were also significantly lower in NPY^{-/-} mice. Furthermore, the number of CD11c⁺ APCs, which phagocytosed fluorescently labeled HDM in the MLNs of NPY^{-/-} mice, were significantly lower than those of NPY^{+/+} mice following sensitization and challenge. Buttari et al. reported that NPY induces dose-dependent migration of human monocyte-derived immature DCs by activating extracellular

regulated kinase and p38 mitogen-activated protein kinases and that this phenomenon was suppressed by a Y₁ receptor antagonist (BIBP-3226) (3). Wheway et al. (36) reported that activation of bone marrow-derived Y₁^{-/-} DCs with lipopolysaccharide led to normal expression of activation markers; however, uptake of an antigen, such as OVA-FITC or FITC-dextran, by immature Y₁^{-/-} DCs decreased compared with that of Y₁^{+/+} immature DCs as determined by a flow cytometry analysis. In our study, the number of CD11c⁺ APCs also decreased significantly in Y₁ receptor antagonist-treated mice compared with vehicle-treated mice. Thus, the NPY-Y₁ axis plays a critical role in the function of DCs in the process of acquired immunity of HDM-induced airway inflammation.

T cells express the Y₁ receptor; therefore, NPY can directly act on T cells. It has been reported that NPY enhances IL-4 production and inhibits IFN-γ production by Th cells (18) and, in the absence of any additional factors, directly induces marked secretion of cytokines (IL-2, IFN-γ, IL-4, and IL-10) from T cells (22). According to these *in vitro* findings, NPY directly induces the cytokine secretion ability of Th cells, particularly Th2 cytokines. *Ex vivo* restimulation of MLN MNCs with OVA resulted in reduced levels of IL-5 and unchanged levels of IFN-γ in NPY^{-/-} mice after sensitization and challenge with OVA compared with NPY^{+/+} mice (26). In their model, sensitization and challenge with OVA did not induce IFN-γ production by T cells. By contrast, in our model, HDM sensitization induced the Th2 and Th1 subtypes. In our study, *ex vivo* restimulation of splenic MNCs with HDM extract resulted in lower production of IL-5, IL-13, and IFN-γ in NPY^{-/-} mice compared with that in NPY^{+/+} mice. *In vivo* sensitization and a deficit of NPY may reduce migration of DCs and differentiation of effector Th cells. DCs have been reported to affect the release of NPY and the activation of Y₁ receptors (35, 36); therefore, NPY^{-/-} DCs were considered to impair its function during *ex vivo* restimulation of splenic MNCs with HDM extract in our study.

ILC2s, a newly identified innate immune cell with the capacity for Th2 cytokine production in response to airway epithelial cell-derived IL-25, IL-33, and TSLP, have been reported to induce the innate immune response and enhance Th2 allergic inflammation (8, 28). ILC2s are associated with corticosteroid-resistant pathophysiology in patients with severe asthma (17). In our study, the levels of IL-33 and the number




Fig. 4. No. of CD11c⁺violet⁺ cells in mediastinal lymph nodes (MLNs) in neuropeptide Y (NPY)^{+/+} and NPY^{-/-} mice. The no. of CD11c⁺violet⁺ cells which phagocytosed labeled house dust mite (HDM) in the lungs was counted by flow cytometry in MLN, as described in MATERIALS AND METHODS. Values are means ± SE (*n* = 5 in each group). #*P* < 0.05.





Fig. 5. The no. of group 2 innate lymphoid cells (ILC2s) and interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP) levels in the lung following sensitization and challenge and neuropeptide Y (NPY) expression in lung tissue. **A**: no. of ILC2s in the lung of NPY^{+/+} and NPY^{-/-} mice after sensitization and challenge. No. of cells in the lung were determined as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 4-5$ in each group). *Significant differences ($P < 0.05$) vs. NPY^{+/+} PBS and NPY^{-/-} PBS mice. There were no differences between NPY^{+/+} house dust mite (HDM) and NPY^{-/-} HDM mice. **B** and **C**: IL-33 and TSLP levels in the lung were measured by ELISA, as described in MATERIALS AND METHODS. *Values are means $\pm$ SE ($n = 8-12$ in each group). Significant differences ($P < 0.05$) vs. NPY^{+/+} PBS and NPY^{-/-} PBS mice. There were no differences between NPY^{+/+} HDM and NPY^{-/-} HDM mice. **D**: immunohistochemical staining of NPY in nonsensitized and nonchallenged NPY^{+/+} mice (**a** and **b**) and HDM-sensitized and -challenged NPY^{+/+} mice (**c** and **d**) with different magnifications (**a** and **c**: $\times 100$, **b** and **d**: $\times 400$). **e**, NPY staining in HDM-sensitized and -challenged NPY^{+/+} mice ($\times 400$). Arrowheads, vascular endothelial cells; bold arrows, mononuclear cells; thin arrows, granulocytes. NPY expression was evaluated by immunohistochemistry 24 h after the last challenge as described in MATERIALS AND METHODS. NPY⁺ cells are indicated by brown staining.

of ILC2s in the lung were analyzed; however, they were not lower in NPY^{-/-} mice or Y₁ receptor antagonist-treated mice than in NPY^{+/+} mice or vehicle-treated mice. Thus, although Y₁ and Y₅ receptors are expressed on airway epithelial cells

(27), the NPY-Y₁ axis may not play a critical role in the secretion of innate cytokines by airway epithelial cells. By contrast, Wallrapp et al. (33) reported that ILC2s express the neuropeptide receptor Nmur1 in steady and activated states.






Fig. 7. No. of T cells and CD11c⁺ antigen-presenting cell (APCs) in the lung following treatment with the Y₁ receptor antagonist (Y₁Ri). *A* and *B*: no. of CD4 and CD8 T cells in the lung after sensitization and challenge. No. of cells in the lung was determined as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 5-9$ in each group). *Significant differences ($P < 0.05$) vs. PBS/vehicle mice. There were no differences between house dust mite (HDM)/vehicle and HDM/Y₁Ri (1 mg/kg) mice. *C*: no. of CD11c⁺ cells in the lungs of neuropeptide Y (NPY)^{+/+} and NPY^{-/-} mice following sensitization and challenge. Values are means $\pm$ SE ($n = 9$ in each group). Significant differences ($P < 0.05$) vs. PBS/vehicle mice (*) and vs. HDM/vehicle mice (#).

Neuromedin U, which is a ligand of Nmur1, activates ILC2s in vitro, and in vivo coadministration of NMU with IL-25 strongly amplifies allergic inflammation (33). In our study, numbers of ILC2s did not differ between NPY^{-/-} and NPY^{+/+} mice; however, the effector function of ILC2s was not fully investigated. Therefore, neuroimmune cross talk in ILCs needs to be further investigated.

NPY receptors are G protein-coupled receptors and consist of at least five subtypes (Y₁, Y₂, Y₄, Y₅, and Y₆) (23). NPY modulates the immune system, particularly via its Y₁ receptor, and the Y₁ receptor is expressed on various immune cells (36). BIBO-3304 is an antagonist of the Y₁ receptor that suppresses NPY-induced food intake after an intraventricular injection (37). In our study, mice treated with a Y₁ receptor antagonist did not show the side effect of reduced body weight. The migration rate of BIBO-3304 to the central nervous system was low; therefore, food intake might not have been affected. Treatment with the Y₁ receptor antagonist only during the challenge phase suppressed AHR and airway inflammation in our study. In the ex vivo restimulation of splenic MNCs with HDM extract experiment, we showed the critical role of NPY in HDM sensitization. DCs present antigens to effector Th cells, and Th cells secrete type 2 cytokines in the airways during the challenge phase. Our data imply that the Y₁ receptor antagonist inhibited those processes and was sufficient to suppress the asthmatic phenotype, indicating the possibility of a treatment for asthmatic patients.

Li et al. showed that increased expression of NPY in airway epithelium of forkhead box p1/p4-deficient mice induced an AHR phenotype in a paracrine manner with airway smooth muscle but without airway inflammation and that NPY ampli-

fied methacholine-induced bronchoconstriction in vitro (24). Wu et al. showed that early postnatal exposure of mice to side-stream tobacco smoke increased the density of NPY nerve fibers in trachea smooth muscle and AHR (39). Thus, the bronchoconstricting action of NPY may worsen the asthmatic phenotype. In contrast, although NPY was reported to cause a contraction in isolated airways of guinea pigs, its bronchoconstricting action was very small, where <6% of responses were elicited by standard spasmogens (4, 32). In our study, methacholine-induced contractions in naïve NPY^{-/-} mice did not differ from that in naïve NPY^{+/+} mice, and the systemic Y₁ receptor antagonist treatment did not suppress methacholine-induced contractions in naïve mice. Although NPY is released with norepinephrine by sympathetic nerve stimulation (9, 38), our study indicates that the role of NPY in cholinergic airway contraction is small under normal conditions. It has also been reported that, in most mammalian species, including mice, there is little innervation of airway smooth muscle by sympathetic fibers (5). Thus, the direct bronchoconstricting action of NPY itself on airway smooth muscle in vivo is controversial.

Repeated allergen challenges have been reported to increase the levels of NPY in BAL fluid (27), and we showed that NPY could increase AHR through activation of the immune response in airway inflammation. Interestingly, NPY was expressed in several cell types in the lung tissue following sensitization and challenge in our study. However, it remains unclear which cell type mainly secretes NPY for eliciting AHR. Further investigations are warranted.

In summary, we identified a critical role for NPY in the development of AHR, airway inflammation, accumulation of CD11c⁺ APCs in the airways, migration of CD11c⁺ APCs in

Fig. 6. Treatment with the Y₁ receptor antagonist (Y₁Ri) suppresses airway hyperresponsiveness (AHR), airway inflammation, and T-helper type 2 (Th2) cytokine levels in bronchoalveolar lavage (BAL) fluid following sensitization and challenge. *A*: AHR after sensitization and challenge with house dust mite (HDM). After the last challenge (24 h), lung resistance was monitored in response to increasing concentrations of inhaled methacholine, as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 8-18$ in each group). Significant differences ($P < 0.05$) vs. PBS/vehicle and PBS/Y₁Ri (1 mg/kg) mice (*), vs. HDM/Y₁Ri (0.1 mg/kg) and HDM/Y₁Ri (1 mg/kg) mice (#). *B*: cellular composition in BAL fluid. Values are means $\pm$ SE ($n = 8-18$ in each group). Significant differences (* $P < 0.05$) vs. PBS/vehicle and PBS/Y₁Ri (1 mg/kg) mice. # $P < 0.05$ vs. HDM/vehicle mice. *C*: development of goblet cell metaplasia in the airways. *D*: goblet cell metaplasia was quantified in periodic acid-Schiff (PAS)-stained sections, as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 6-7$ in each group). Significant differences ($P < 0.05$) vs. PBS/vehicle and PBS/Y₁Ri (1 mg/kg) mice (*), vs. HDM/vehicle mice (#). *E-G*: Th2 cytokine levels [interleukin (IL)-4, IL-5, and IL-13] in BAL fluid were measured by ELISA, as described in MATERIALS AND METHODS. Values are means $\pm$ SE ($n = 8-18$ in each group). Significant differences ($P < 0.05$) vs. PBS/vehicle and PBS/Y₁Ri (1 mg/kg) mice (*) and vs. HDM/vehicle mice (#). Mac, macrophage; Lym, lymphocyte; Neu, neutrophil; Eos, eosinophil.

MLNs, and activation of Th2 cells. Furthermore, we demonstrated that a Y₁ receptor antagonist attenuated AHR and airway inflammation. Our data imply that controlling the NPY-Y₁ axis will provide a novel interventional strategy for treating asthma.

ACKNOWLEDGMENTS

We thank Dr. Noboru Asada and Mitsune Tanimoto, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and Yasuharu Sato, Division of Pathology, Okayama University Graduate School of Health Sciences, for helpful advice and discussions.

GRANTS

This work was supported in part by Novartis Pharma Research grant (to N. Miyahara) and Daiichi-Sankyo Research Grant A17-1612 (to N. Miyahara).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

N.O. and N.M. conceived and designed research; N.O., A.T., D.M., S.S., U.F., J.I., and Y.G. performed experiments; N.O., N.M., A.T., D.M., S.S., J.I., and Y.G. analyzed data; N.O., N.M., A.T., D.M., S.S., U.F., K.K., A.K., and Y.M. interpreted results of experiments; N.O., A.T., J.I., and Y.G. prepared figures; N.O., N.M., and A.T. drafted manuscript; N.O., N.M., A.T., and Y.G. edited and revised manuscript; N.O., N.M., A.T., D.M., S.S., U.F., J.I., Y.G., K.K., A.K., and Y.M. approved final version of manuscript.

REFERENCES

- Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 11, Suppl 5: S322–S328, 2014. doi:10.1513/AnnalsATS.201403-118AW.
- Busse WW, Lemanske RF Jr. Asthma. *N Engl J Med* 344: 350–362, 2001. doi:10.1056/NEJM200102013440507.
- Buttari B, Profumo E, Domenici G, Tagliani A, Ippoliti F, Bonini S, Businaro R, Elenkov I, Riganò R. Neuropeptide Y induces potent migration of human immature dendritic cells and promotes a Th2 polarization. *FASEB J* 28: 3038–3049, 2014. doi:10.1096/fj.13-243485.
- Cadieux A, Benckroun MT, St-Pierre S, Fournier A. Bronchoconstrictor action of neuropeptide Y (NPY) in isolated guinea pig airways. *Neuropeptides* 13: 215–219, 1989. doi:10.1016/0143-4179(89)90073-5.
- Canning BJ, Fischer A. Neural regulation of airway smooth muscle tone. *Respir Physiol* 125: 113–127, 2001. doi:10.1016/S0034-5687(00)00208-5.
- Cardell LO, Uddman R, Edvinsson L. Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. *Eur Respir J* 7: 2169–2173, 1994. doi:10.1183/09031936.94.07122169.
- Dahlöf C, Dahlöf P, Lundberg JM, Strömbom U. Elevated plasma concentration of neuropeptide Y and low level of circulating adrenaline in elderly asthmatics during rest and acute severe asthma. *Pulm Pharmacol* 1: 3–6, 1988. doi:10.1016/0952-0600(88)90003-8.
- Deckers J, Branco Madeira F, Hammad H. Innate immune cells in asthma. *Trends Immunol* 34: 540–547, 2013. doi:10.1016/j.it.2013.08.004.
- Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Håkanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. *Regul Pept* 8: 225–235, 1984. doi:10.1016/0167-0115(84)90064-8.
- Fujii U, Miyahara N, Taniguchi A, Oda N, Morichika D, Murakami E, Nakayama H, Waseda K, Kataoka M, Kakuta H, Tanimoto M, Kanehiro A. Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthma. *Respir Res* 18: 23, 2017. doi:10.1186/s12931-017-0507-z.
- Fujii U, Miyahara N, Taniguchi A, Waseda K, Morichika D, Kurimoto E, Koga H, Kataoka M, Gelfand EW, Cua DJ, Yoshimura A, Tanimoto M, Kanehiro A. IL-23 is essential for the development of elastase-induced pulmonary inflammation and emphysema. *Am J Respir Cell Mol Biol* 55: 697–707, 2016. doi:10.1165/rcmb.2016-0015OC.
- Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet MR, Zaph C, Takei F, McNagny KM. Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. *J Allergy Clin Immunol* 133: 1142–1148, 2014. doi:10.1016/j.jaci.2014.02.033.
- Howarth PH, Springall DR, Redington AE, Djukanovic R, Holgate ST, Polak JM. Neuropeptide-containing nerves in endobronchial biopsies from asthmatic and nonasthmatic subjects. *Am J Respir Cell Mol Biol* 13: 288–296, 1995. doi:10.1165/ajrcmb.13.3.7654385.
- Ikeda G, Miyahara N, Koga H, Fuchimoto Y, Waseda K, Kurimoto E, Taniguchi A, Tanimoto Y, Kataoka M, Tanimoto M, Kanehiro A. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. *Am J Respir Cell Mol Biol* 50: 18–29, 2014. doi:10.1165/rcmb.2012-0418OC.
- Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. *N Engl J Med* 377: 965–976, 2017. doi:10.1056/NEJMra1608969.
- Jaakkola U, Kakko T, Juonala M, Lehtimäki T, Viikari J, Jääskeläinen AE, Mononen N, Kähönen M, Koskinen T, Keltikangas-Järvinen L, Raitakari O, Kallio J. Neuropeptide Y polymorphism increases the risk for asthma in overweight subjects: protection from atherosclerosis in asthmatic subjects—the cardiovascular risk in young Finns study. *Neuropeptides* 46: 321–328, 2012. doi:10.1016/j.npep.2012.09.005.
- Kabata H, Moro K, Fukunaga K, Suzuki Y, Miyata J, Masaki K, Betsuyaku T, Koyasu S, Asano K. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. *Nat Commun* 4: 2675, 2013. doi:10.1038/ncomms3675.
- Kawamura N, Tamura H, Obana S, Wenner M, Ishikawa T, Nakata A, Yamamoto H. Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. *Neuroimmunomodulation* 5: 9–15, 1998. doi:10.1159/000026321.
- Koga H, Miyahara N, Fuchimoto Y, Ikeda G, Waseda K, Ono K, Tanimoto Y, Kataoka M, Gelfand EW, Tanimoto M, Kanehiro A. Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responses. *Respir Res* 14: 8, 2013. doi:10.1186/1465-9921-14-8.
- Kurimoto E, Miyahara N, Kanehiro A, Waseda K, Taniguchi A, Ikeda G, Koga H, Nishimori H, Tanimoto Y, Kataoka M, Iwakura Y, Gelfand EW, Tanimoto M. IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice. *Respir Res* 14: 5, 2013. doi:10.1186/1465-9921-14-5.
- Lee NA, Gelfand EW, Lee JJ. Pulmonary T cells and eosinophils: coconspirators or independent triggers of allergic respiratory pathology? *J Allergy Clin Immunol* 107: 945–957, 2001. doi:10.1067/mai.2001.116002.
- Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. *Proc Natl Acad Sci USA* 95: 12544–12549, 1998. doi:10.1073/pnas.95.21.12544.
- Lin S, Boey D, Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. *Neuropeptides* 38: 189–200, 2004. doi:10.1016/j.npep.2004.05.005.
- Li S, Koziol-White C, Jude J, Jiang M, Zhao H, Cao G, Yoo E, Jester W, Morley MP, Zhou S, Wang Y, Lu MM, Panettieri RA Jr, Morrissey EE. Epithelium-generated neuropeptide Y induces smooth muscle contraction to promote airway hyperresponsiveness. *J Clin Invest* 126: 1978–1982, 2016. doi:10.1172/JCI81389.
- Lu Y, Andiappan AK, Lee B, Ho R, Lim TK, Kuan WS, Goh DY, Mahadevan M, Sim TB, Wang Y, Van Bever HP, Rotzschke O, Larbi A, Ng TP. Neuropeptide Y associated with asthma in young adults. *Neuropeptides* 59: 117–121, 2016. doi:10.1016/j.npep.2016.07.003.
- Macia L, Rao PT, Wheway J, Sierro F, Mackay F, Herzog H. Y1 signalling has a critical role in allergic airway inflammation. *Immunol Cell Biol* 89: 882–888, 2011. doi:10.1038/icb.2011.6.
- Makinde TO, Steininger R, Agrawal DK. NPY and NPY receptors in airway structural and inflammatory cells in allergic asthma. *Exp Mol Pathol* 94: 45–50, 2013. doi:10.1016/j.yexmp.2012.05.009.
- Scanlon ST, McKenzie AN. The messenger between worlds: the regulation of innate and adaptive type-2 immunity by innate lymphoid cells. *Clin Exp Allergy* 45: 9–20, 2015. doi:10.1111/cea.12464.
- Sheppard MN, Polak JM, Allen JM, Bloom SR. Neuropeptide tyrosine (NPY): a newly discovered peptide is present in the mammalian respiratory tract. *Thorax* 39: 326–330, 1984. doi:10.1136/thx.39.5.326.
- Steinman RM, Kaplan G, Witmer MD, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. *J Exp Med* 149: 1–16, 1979. doi:10.1084/jem.149.1.1.

31. Taniguchi A, Miyahara N, Waseda K, Kurimoto E, Fujii U, Tanimoto Y, Kataoka M, Yamamoto Y, Gelfand EW, Yamamoto H, Tanimoto M, Kanehiro A. Contrasting roles for the receptor for advanced glycation end-products on structural cells in allergic airway inflammation vs. airway hyperresponsiveness. *Am J Physiol Lung Cell Mol Physiol* 309: L789–L800, 2015. doi:10.1152/ajplung.00087.2015.
32. T-Benchekroun M, Fournier A, St-Pierre S, Cadieux A. Inhibitory action of neuropeptide Y on agonist-induced responses in isolated guinea pig trachea. *Eur J Pharmacol* 216: 421–428, 1992. doi:10.1016/0014-2999(92)90440-F.
33. Wallrapp A, Riesenfeld SJ, Burkett PR, Abdunnour RE, Nyman J, Dionne D, Hofree M, Cuoco MS, Rodman C, Farouq D, Haas BJ, Tickle TL, Trombetta JJ, Baral P, Klose CSN, Mahlaköiv T, Artis D, Rozenblatt-Rosen O, Chiu IM, Levy BD, Kowalczyk MS, Regev A, Kuchroo VK. The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation. *Nature* 549: 351–356, 2017. doi:10.1038/nature24029.
34. Waseda K, Miyahara N, Taniguchi A, Kurimoto E, Ikeda G, Koga H, Fujii U, Yamamoto Y, Gelfand EW, Yamamoto H, Tanimoto M, Kanehiro A. Emphysema requires the receptor for advanced glycation end-products triggering on structural cells. *Am J Respir Cell Mol Biol* 52: 482–491, 2015. doi:10.1165/rcmb.2014-0027OC.
35. Wheway J, Herzog H, Mackay F. The Y1 receptor for NPY: a key modulator of the adaptive immune system. *Peptides* 28: 453–458, 2007. doi:10.1016/j.peptides.2006.09.030.
36. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, Mackay F. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. *J Exp Med* 202: 1527–1538, 2005. doi:10.1084/jem.20051971.
37. Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. *Br J Pharmacol* 125: 549–555, 1998. doi:10.1038/sj.bjp.0702084.
38. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. *J Neuroimmunol* 172: 38–58, 2006. doi:10.1016/j.jneuroim.2005.10.017.
39. Wu ZX, Benders KB, Hunter DD, Dey RD. Early postnatal exposure of mice to side-stream tobacco smoke increases neuropeptide Y in lung. *Am J Physiol Lung Cell Mol Physiol* 302: L152–L159, 2012. doi:10.1152/ajplung.00071.2011.

